1. Home
  2. ACXP vs IRD Comparison

ACXP vs IRD Comparison

Compare ACXP & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACXP
  • IRD
  • Stock Information
  • Founded
  • ACXP 2017
  • IRD 2018
  • Country
  • ACXP United States
  • IRD United States
  • Employees
  • ACXP N/A
  • IRD 14
  • Industry
  • ACXP Biotechnology: Pharmaceutical Preparations
  • IRD
  • Sector
  • ACXP Health Care
  • IRD
  • Exchange
  • ACXP Nasdaq
  • IRD NYSE
  • Market Cap
  • ACXP 31.4M
  • IRD 36.3M
  • IPO Year
  • ACXP 2021
  • IRD N/A
  • Fundamental
  • Price
  • ACXP $0.78
  • IRD $1.15
  • Analyst Decision
  • ACXP Strong Buy
  • IRD Strong Buy
  • Analyst Count
  • ACXP 1
  • IRD 1
  • Target Price
  • ACXP $12.00
  • IRD $8.00
  • AVG Volume (30 Days)
  • ACXP 273.8K
  • IRD 154.1K
  • Earning Date
  • ACXP 03-14-2025
  • IRD 02-19-2025
  • Dividend Yield
  • ACXP N/A
  • IRD N/A
  • EPS Growth
  • ACXP N/A
  • IRD N/A
  • EPS
  • ACXP N/A
  • IRD N/A
  • Revenue
  • ACXP N/A
  • IRD $8,381,000.00
  • Revenue This Year
  • ACXP N/A
  • IRD N/A
  • Revenue Next Year
  • ACXP N/A
  • IRD $29.37
  • P/E Ratio
  • ACXP N/A
  • IRD N/A
  • Revenue Growth
  • ACXP N/A
  • IRD N/A
  • 52 Week Low
  • ACXP $0.68
  • IRD $0.81
  • 52 Week High
  • ACXP $3.35
  • IRD $2.77
  • Technical
  • Relative Strength Index (RSI)
  • ACXP 46.10
  • IRD N/A
  • Support Level
  • ACXP $0.70
  • IRD N/A
  • Resistance Level
  • ACXP $0.82
  • IRD N/A
  • Average True Range (ATR)
  • ACXP 0.06
  • IRD 0.00
  • MACD
  • ACXP 0.01
  • IRD 0.00
  • Stochastic Oscillator
  • ACXP 40.10
  • IRD 0.00

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: